To hear about similar clinical trials, please enter your email below
Trial Title:
18F-FAPI-RGD PET/CT in Various Tumor Types
NCT ID:
NCT06094530
Condition:
Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with
various types of tumor, and the results will be compared with those of 18F-FDG.
Detailed description:
The aim of this study is to evaluate, in patients with various types of tumor, the
radiotracer uptake and clinical feasibility of 18F-FAPI-RGD PET/CT compared with those of
18F-FDG PET/CT. To evaluate the diagnostic performance of 18F-FAPI-RGD and 18F-FDG PET
imaging, the results of the visually interpreted PET images will be compared with the
histopathologic results (via surgery or biopsy), which are used as the gold standard for
the final diagnosis. For patients for whom tissue diagnosis is not applicable, clinical
and radiographic follow-up data will be used as the reference standard to validate the
PET/CT findings.
Criteria for eligibility:
Study pop:
Patients with clinically suspected or diagnosed tumors
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients with clinically suspected or diagnosed tumors
Exclusion Criteria:
- Hypertension that is difficult to control with medication, and systolic blood
pressure exceeding 160mmHg
- Complicated with chronic liver disease, myocardial infarction, stroke
- Female patients who are pregnant (or attempting to become pregnant within six
months), breastfeeding, or unwilling to use contraception
- Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying
for 20 minutes
Gender:
All
Minimum age:
10 Years
Maximum age:
80 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital
Address:
City:
Chengdu
Zip:
610072
Country:
China
Status:
Recruiting
Contact:
Last name:
Hao Wang, Doctor
Phone:
+8618313820216
Email:
474556259@qq.com
Start date:
April 10, 2023
Completion date:
October 2024
Lead sponsor:
Agency:
Sichuan Provincial People's Hospital
Agency class:
Other
Source:
Sichuan Provincial People's Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06094530
